StockStory.org on MSN
Moderna (MRNA): Buy, sell, or hold post Q1 earnings?
The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting ...
Moderna (MRNA) reported $108 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 35.3%. EPS of -$2.52 for the same period compares to -$3.07 a year ago. The ...
For the quarter ended September 2025, Moderna (MRNA) reported revenue of $1.02 billion, down 45.4% over the same period last year. EPS came in at -$0.51, compared to $0.03 in the year-ago quarter. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results